NATURE REVIEWS DRUG DISCOVERY自然综述：药物发现
NATURE REVIEWS DRUG DISCOVERY(英文缩写 NAT REV DRUG DISCOV),ISSN 1474-1776,eISSN 1474-1784,中文译名:自然综述：药物发现 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 112.288 | Q1 |
| 2022 | 120.100 | Q1 |
| 2023 | 122.700 | Q1 |
| 2024 | 101.800 | Q1 |
| 2025 | 91.200 | Q1 |
NATURE REVIEWS DRUG DISCOVERY 最新收录文献
-
1. Refining therapeutic targeting of interleukin-6 by signalling mode selectivity.
PMID:日期:2026-09-23Interleukin-6 (IL-6) is a multifunctional cytokine that regulates immunity, tissue repair and metabolic homeostasis, while also driving chronic inflammation in a broad range of diseases. IL-6 exerts its effects through distinct signalling modes, including classic signalling via its membrane-bound receptor (IL-6R) and trans-signalling via the soluble IL-6R (sIL-6R), which expands IL-6 responsiveness to most if not all cell types. Therapeutic targeting of the IL-6 pathway - primarily through monoclonal antibodies neutralizing IL-6 or IL-6R and Janus kinase (JAK) inhibitors targeting downstream signalling - has transformed the treatment of several autoimmune diseases but has also highlighted safety concerns linked to the homeostatic functions of IL-6. Advances in the understanding of IL-6 signalling biology, including endogenous regulation by soluble glycoprotein 130 kDa (sgp130) and the regulation of trans-signalling by a disintegrin and metalloproteinase 17 (ADAM17), have renewed interest in strategies that allow selective pathway modulation. In this Review, we outline the molecular basis of IL-6 signalling, examine the differential roles of classic and trans-signalling in experimental and clinical disease, and compare global and selective IL-6-targeted therapeutic approaches. We focus on the emerging concept of mechanistic and clinical differentiation within the IL-6 pathway and its implications for future drug development.
-
6. The evolving landscape of drug targets.
PMID:日期:2026-09-21Since the turn of the century, drug discovery has been transformed by advances in genetics, genomics and proteomics, as well as automation, data science and the diversification of therapeutic modalities beyond synthetic small molecules and natural product derivatives. This transformation has led to the expansion of the drug target landscape, enabling advances in the treatment of many diseases, including some that previously lacked pharmacotherapies. In this Review, we map and quantify key elements of these changes over the past 25 years, such as trends in the number and type of targets through which drugs mediate their therapeutic effects, which now include 686 biomolecules modulated by 1,702 drugs. We also discuss trends we believe will continue or change, as target druggability continues to evolve with the emergence of new therapeutic modalities.
-
9. First myostatin-targeted antibody approved for spinal muscular atrophy.
PMID:日期:2026-09-18该文献暂无摘要。
-
10. Selective oestrogen receptor degrader class grows with new cancer approval.
PMID:日期:2026-09-11该文献暂无摘要。